Skip to content

Clinical trials

Substance-Related Disorders trials in the United States with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Substance-Related Disorders Status: Unknown status Country / region: United States Clear all

73 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20022
20032
20054
20072
20082
20094
20115
20122
20133
20141
20153
20163
20174
20182
20193
20208
20214
202210
20233
20243

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status73

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute on Drug Abuse (NIDA)6
The University of Tennessee, Knoxville4
George Mason University3
Kaiser Permanente2
Massachusetts General Hospital2
National Development and Research Institutes, Inc.2
The University of Texas Health Science Center, Houston2
University of Illinois at Urbana-Champaign2
Wayne State University2
American Society Of Thermalism And Climatology Inc1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Substance-Related Disorders73
Alcoholism11
Opioid-Related Disorders10
Marijuana Abuse5
Acquired Immunodeficiency Syndrome3
Anxiety Disorders3
Mental Disorders3
Stress Disorders, Post-Traumatic3
Tobacco Use Disorder3
Alcohol-Related Disorders2

Trials

Showing 1 to 25 of 73. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.